Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma

Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma

Abstract Several biomarkers such as tumor mutation burden (TMB), neoantigen load (NAL), programmed cell‐death receptor 1 ligand (PD‐L1) expression, and lactate dehydrogenase (LDH) have been developed for predicting response to immune checkpoint inhibitors (ICIs) in melanoma. However, some limitation...

Full description

Bibliographic Details
Main Authors: Junjie Jiang, Yongfeng Ding, Mengjie Wu, Yanyan Chen, Xiadong Lyu, Jun Lu, Haiyong Wang, Lisong Teng
Format: Article
Language:English
Published: Wiley 2020-11-01
Series:Cancer Medicine
Subjects:
biomarker
durable clinical benefit
immune checkpoint inhibitors
melanoma
Online Access:https://doi.org/10.1002/cam4.3481

Internet

https://doi.org/10.1002/cam4.3481

Similar Items